Actively Recruiting
Study of Membrane-inhibiting Formula Plus Oral Progestins for Fertility-Preserving Treatment in Women with Early Endometrial Cancer or Hyperplasia
Led by Women's Hospital School Of Medicine Zhejiang University · Updated on 2024-05-16
75
Participants Needed
1
Research Sites
74 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects and possible side effects of a membrane-inhibiting formula combined with oral progestins as a fertility-preserving treatment for women with early-stage endometrial cancer and endometrial hyperplasia. The study aims to find out whether this combination shortens the time needed for complete endometrial remission and to monitor outcomes such as treatment efficacy, side effects, recurrence, pregnancy rates, and time to pregnancy in different molecular subtypes of the disease. Participants will take the membrane-inhibiting formula along with the oral progestin drug megestrol acetate at a dose of 160mg once daily for 24 weeks. They will visit the clinic every 3 months for checkups, tests, and hysteroscopy to monitor progress. The study tracks responses at multiple time points including baseline, 12, 24, 36, and 48 weeks to assess complete remission rates and treatment-related adverse events. During the study, participants will keep a diary of examination results and pathology findings. Researchers will monitor safety and treatment effects through regular clinical visits and tests. The primary outcome is the complete response rate at 24 weeks, with additional evaluations up to 48 weeks and pregnancy outcomes assessed one year after remission. The total participation duration includes ongoing follow-up visits to assess recurrence and pregnancy rates.
CONDITIONS
Brief Title
Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women
Research Team
Y
Yang Li, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here